TG Therapeutics (NASDAQ:TGTX) Upgraded at Zacks Research

Zacks Research upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a strong sell rating to a hold rating in a research report report published on Tuesday,Zacks reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings raised TG Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, September 21st. Bank of America increased their price objective on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Jefferies Financial Group restated a “buy” rating and issued a $83.00 target price on shares of TG Therapeutics in a research report on Monday, June 22nd. HC Wainwright reaffirmed a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. Finally, JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $63.00.

TG Therapeutics Stock Up 0.7%

TG Therapeutics stock opened at $53.34 on Tuesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. TG Therapeutics has a one year low of $26.76 and a one year high of $59.30. The company has a 50-day simple moving average of $53.60 and a 200-day simple moving average of $47.24. The firm has a market capitalization of $8.16 billion, a P/E ratio of 19.47, a P/E/G ratio of 2.27 and a beta of 1.80.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company’s revenue for the quarter was up 70.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.17 earnings per share. As a group, equities analysts expect that TG Therapeutics will post 0.92 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director owned 168,640 shares in the company, valued at $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.87% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TGTX. GAMMA Investing LLC boosted its stake in TG Therapeutics by 15.4% during the 3rd quarter. GAMMA Investing LLC now owns 5,929 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 789 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of TG Therapeutics by 45.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 312 shares during the period. Cim Investment Management Inc. bought a new stake in shares of TG Therapeutics in the 2nd quarter worth $349,000. Envestnet Portfolio Solutions Inc. raised its stake in shares of TG Therapeutics by 24.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 21,192 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 4,215 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of TG Therapeutics in the 2nd quarter worth $1,351,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways.

TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.